Can a Two-Drug punch knock out CMV faster in lung transplants?
NCT ID NCT07235683
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests whether adding letermovir to standard antiviral treatment helps clear cytomegalovirus (CMV) infection faster in people who have received a lung transplant. About 40 participants will receive either letermovir or a placebo alongside their usual medication for 21 days. The main goal is to see if more patients achieve a negative CMV test by week three.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Letermovir (an antiviral drug) plus standard antiviral therapy (valganciclovir/ganciclovir)
What this could lead to
If successful, this combination could help lung transplant patients clear CMV infections more quickly, reducing complications and improving recovery.
What could go wrong
This is a small pilot trial with only 40 participants, so results may not apply broadly. Adding letermovir could also increase side effects or drug interactions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT RECIPIENT are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University Health Network, Toronto General Hospital
RECRUITINGToronto, Ontario, M5G 2C4, Canada
Contact Phone: •••-•••-•••• Email: •••••@•••••